Eugia Pharma Specialities receives USFDA warning for Unit III

16 Aug 2024

Eugia Pharma Specialities receives USFDA warning for Unit III

Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugia Pharma Specialities, a subsidiary of the company. There is no impact on the existing supplies to the US market.

The warning letter comes subsequent to receiving the Official Action Indicated (OAI) status from USFDA earlier in May 2024.

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions